• Wondering whether Baxter International at US$17.30 is a potential bargain or a value trap? This article focuses squarely on what the current price might imply about the stock.
• The stock has been under pressure, with returns down 3.8% over the past week, 1.7% over the past month, 11.3% year to date and 44.6% over the last year. The three and five year returns are down 56.9% and 76.9% respectively.
• These moves sit against a backdrop of ongoing attention on Baxter International's medical equipment portfolio and capital structure, as investors weigh the company’s positioning in the healthcare sector and its balance sheet strength. Recent coverage has focused on how the stock's long term share price record and current valuation metrics interact with that backdrop.
• On Simply Wall St’s 6 point valuation checklist, Baxter International currently scores 5 out of 6. This sets up a closer look at discounted cash flow models, multiples and other methods, with an even more practical way to think about valuation coming at the end of this article.

Approach 1: Baxter International Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock could be worth by projecting the company’s future cash flows and discounting them back to today’s value. It focuses on cash that may ultimately be available to shareholders rather than on accounting earnings.

For Baxter International, the model used is a 2 stage Free Cash Flow to Equity approach, based on cash flows in $. The latest twelve month free cash flow is about $751.4 million. Analysts provide explicit forecasts out to 2028, where free cash flow is projected at $899 million, and Simply Wall St then extrapolates these trends out to 2035 using its own assumptions.

After discounting these projected cash flows, the model arrives at an estimated intrinsic value of $25.96 per share. Compared with the current share price of $17.30, this implies the stock trades at about a 33.4% discount to the DCF estimate, which suggests that, on this cash flow view, Baxter International appears undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Baxter International is undervalued by 33.4%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Baxter International Price vs Sales

For companies in medical equipment, revenue-based metrics such as the P/S ratio are often useful because sales are typically more stable and less affected by accounting items than earnings. Higher expected growth and lower perceived risk can justify a higher P/S multiple, while slower growth or higher risk usually point to a lower, more conservative range.

Baxter International currently trades on a P/S ratio of 0.79x. The Medical Equipment industry average is 2.71x, and the peer group used by Simply Wall St sits at 6.49x, so the stock is priced at a discount to both of these benchmarks. Simply Wall St’s proprietary Fair Ratio for Baxter International is 1.11x. This Fair Ratio reflects factors such as earnings growth expectations, industry, profit margins, market cap and company specific risks, which makes it a more tailored guide than broad peer or industry comparisons.

Comparing Baxter International’s current P/S of 0.79x with the Fair Ratio of 1.11x indicates the stock is trading below the level implied by those fundamentals.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Baxter International Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, which let you pair your view of Baxter International’s story with concrete numbers by setting assumptions for future revenue, earnings and margins, linking that forecast to a Fair Value that you can then compare with today’s share price on Simply Wall St’s Community page.

A Narrative is your own storyline about what you think is happening at the company and in its industry, translated into a forecast and a Fair Value. Instead of only relying on a single DCF or multiple, you see how your expectations stack up against the market price and decide whether that gap is large enough to consider buying, holding or selling.

Because Narratives on Simply Wall St are refreshed when new earnings, news or guidance are released, you always see an updated Fair Value. For Baxter International that means you can compare, for example, one Narrative that anchors to a cautious Fair Value of about US$18.00 with another that uses a much higher Fair Value around US$33.29, then decide which story and set of assumptions feels closer to your own view.

Do you think there's more to the story for Baxter International? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.